Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (311-320 of 584) with videos related to

Pageof 59
Sort By:
Blood|August 30, 2003
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 settingRazelle Kurzrock, Hagop M Kantarjian, Jorge E Cortes, et al.
Biological Trace Element Research|January 1, 1994
Toxic heavy metals and other trace elements in foodstuffs from 12 different countries. An IAEA coordinated research programE Cortes Toro, H A Das, J J Fardy, et al.
American Journal of Clinical Oncology|June 1, 1984
A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B studyD C Tormey, V E Weinberg, L A Leone, et al.
Cancer|July 29, 2015
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsMusa Yilmaz, Amit Lahoti, Susan O'Brien, et al.
Journal of Hematology & Oncology|April 19, 2015
Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosisWei Wang, Guilin Tang, Jorge E Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndromeStefan Faderl, Guillermo Garcia-Manero, Zeev Estrov, et al.
Haematologica|July 15, 2003
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blastsMarina Konopleva, Su-Chun Cheng, Jorge E Cortes, et al.
Cancer|July 14, 2011
Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trialMaria E Cabanillas, Hagop Kantarjian, Deborah A Thomas, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2016
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH StudyJorge E Cortes, Jeffrey H Lipton, Carole B Miller, et al.
Cancer|April 17, 2018
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromeRita Assi, Hagop M Kantarjian, Tapan M Kadia, et al.
Pageof 59

Showing results (311-320 of 584) with videos related to

Sort By:
Pageof 59
Blood|August 30, 2003
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 settingRazelle Kurzrock, Hagop M Kantarjian, Jorge E Cortes, et al.
Biological Trace Element Research|January 1, 1994
Toxic heavy metals and other trace elements in foodstuffs from 12 different countries. An IAEA coordinated research programE Cortes Toro, H A Das, J J Fardy, et al.
American Journal of Clinical Oncology|June 1, 1984
A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B studyD C Tormey, V E Weinberg, L A Leone, et al.
Cancer|July 29, 2015
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsMusa Yilmaz, Amit Lahoti, Susan O'Brien, et al.
Journal of Hematology & Oncology|April 19, 2015
Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosisWei Wang, Guilin Tang, Jorge E Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndromeStefan Faderl, Guillermo Garcia-Manero, Zeev Estrov, et al.
Haematologica|July 15, 2003
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blastsMarina Konopleva, Su-Chun Cheng, Jorge E Cortes, et al.
Cancer|July 14, 2011
Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trialMaria E Cabanillas, Hagop Kantarjian, Deborah A Thomas, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2016
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH StudyJorge E Cortes, Jeffrey H Lipton, Carole B Miller, et al.
Cancer|April 17, 2018
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromeRita Assi, Hagop M Kantarjian, Tapan M Kadia, et al.
Pageof 59